Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine whether Integrated Treatment is effective in the treatment of anxiety and/or depression with co-occurring substance use disorders.

Detailed Description
-----------------
Patients with mental disorders and co-occuring substance use disorders are characterized by high suicide rates, high treatment drop-out rates and long-lasting interpersonal, work, school, health and legal problems. Because mental disorders and substance use disorders co-exist and interact, it may be important to provide a treatment that addresses the substance misuse and mental health problems in an integrated and comprehensive way. Additionally, the health services for patients with mental health and substance use disorders are usually provided by different services and health professionals that rarely cooperate or have qualifications on both kinds of disorders. This also calls for an integration of the services on an organizational level. This approach of integrating services and treatment approaches for both diseases in a comprehensive way is called Integrated Treatment. Several studies have shown that Integrated Treatment is effective in treating the comorbidity of severe mental illness and substance use disorders. The over-all aim of this study is to evaluate the effects of evidence-based Integrated Treatment in anxiety and/or depression with co-occurring substance use disorders. The effects of the treatment will be assesses on changes in substance use and psychopathology. Comparison: patients receiving treatment-as-usual or non-manualized treatment at general mental health outpatients clinics.

Official Title
-----------------
Effects of Integrated Treatment to Persons With Mental Disorders and Co-occurring Substance Use Disorders

Conditions
-----------------
Anxiety Disorders, Mood Disorders, Substance Use Disorders

Intervention / Treatment
-----------------
* Behavioral: Integrated mental health and substance use treatment
* Behavioral: Treatment as usual


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis of substance use disorder clinical diagnosis of anxiety disorders clinical diagnosis of nonpsychotic mood disorders written consent planning to live in the catchment area during the treatment Exclusion Criteria: schizophrenia spectrum disorders other psychotic disorders mental retardation nicotine abuse/dependency only prescription drug abuse/dependency only planning to move out of the catchment area during the study not able to read or write Norwegian

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Integrated treatment<br>Evidence-based psychosocial and pharmacological treatment of both the substance use disorder and the mental health disorder is provided at the same time and by the same therapists in a comprehensive way. | Behavioral: Integrated mental health and substance use treatment<br>* Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.<br>* Other names: co-occurring disorders;|
| Active Comparator: Treatment as usual<br>Non-manualized clinic-based treatment provided by therapists without formal training in integrated treatment of co-occurring disorders. | Behavioral: Treatment as usual<br>* Non-standardized psychiatric outpatient treatment<br>* Other names: non-manualized;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Symptom Check List 90 (SCL90-r), The Alcohol Use Disorder Identification Test (AUDIT), The Drug Use Disorder Identification Test (DUDIT). | We use the SCL-90r to measure symptoms in regard to anxiety, depression and the General Severity Index. We use the AUDIT and the DUDIT to measure changes in the use of alcohol and illegal drugs respectively. | Change during 6 and 12 months follow-up | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The Addiction Severity Index (Europ ASI) | The Addiction Severity Index (Europ ASI) is used to assess changes in the use of alcohol and illegal substances during the course of the trial. | Change during 6 and 12 months follow up | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mental health, substance use, treatment